Cargando…
Dramatic Response to Teriprilumab and Anlotinib Combination Therapy in a patient with EGFR-Mutant Lung Adenocarcinoma Who Experienced Small-Cell Transformation−Mediated Erlotinib Resistance After Failure of Chemotherapy
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474210/ https://www.ncbi.nlm.nih.gov/pubmed/34589923 http://dx.doi.org/10.1016/j.jtocrr.2020.100010 |
| _version_ | 1784575162512834560 |
|---|---|
| author | Zhou, Yuling Zeng, Liang Yang, Nong Zhang, Yongchang |
| author_facet | Zhou, Yuling Zeng, Liang Yang, Nong Zhang, Yongchang |
| author_sort | Zhou, Yuling |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8474210 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Elsevier |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-84742102021-09-28 Dramatic Response to Teriprilumab and Anlotinib Combination Therapy in a patient with EGFR-Mutant Lung Adenocarcinoma Who Experienced Small-Cell Transformation−Mediated Erlotinib Resistance After Failure of Chemotherapy Zhou, Yuling Zeng, Liang Yang, Nong Zhang, Yongchang JTO Clin Res Rep Case Report Elsevier 2020-02-11 /pmc/articles/PMC8474210/ /pubmed/34589923 http://dx.doi.org/10.1016/j.jtocrr.2020.100010 Text en © 2020 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| spellingShingle | Case Report Zhou, Yuling Zeng, Liang Yang, Nong Zhang, Yongchang Dramatic Response to Teriprilumab and Anlotinib Combination Therapy in a patient with EGFR-Mutant Lung Adenocarcinoma Who Experienced Small-Cell Transformation−Mediated Erlotinib Resistance After Failure of Chemotherapy |
| title | Dramatic Response to Teriprilumab and Anlotinib Combination Therapy in a patient with EGFR-Mutant Lung Adenocarcinoma Who Experienced Small-Cell Transformation−Mediated Erlotinib Resistance After Failure of Chemotherapy |
| title_full | Dramatic Response to Teriprilumab and Anlotinib Combination Therapy in a patient with EGFR-Mutant Lung Adenocarcinoma Who Experienced Small-Cell Transformation−Mediated Erlotinib Resistance After Failure of Chemotherapy |
| title_fullStr | Dramatic Response to Teriprilumab and Anlotinib Combination Therapy in a patient with EGFR-Mutant Lung Adenocarcinoma Who Experienced Small-Cell Transformation−Mediated Erlotinib Resistance After Failure of Chemotherapy |
| title_full_unstemmed | Dramatic Response to Teriprilumab and Anlotinib Combination Therapy in a patient with EGFR-Mutant Lung Adenocarcinoma Who Experienced Small-Cell Transformation−Mediated Erlotinib Resistance After Failure of Chemotherapy |
| title_short | Dramatic Response to Teriprilumab and Anlotinib Combination Therapy in a patient with EGFR-Mutant Lung Adenocarcinoma Who Experienced Small-Cell Transformation−Mediated Erlotinib Resistance After Failure of Chemotherapy |
| title_sort | dramatic response to teriprilumab and anlotinib combination therapy in a patient with egfr-mutant lung adenocarcinoma who experienced small-cell transformation−mediated erlotinib resistance after failure of chemotherapy |
| topic | Case Report |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474210/ https://www.ncbi.nlm.nih.gov/pubmed/34589923 http://dx.doi.org/10.1016/j.jtocrr.2020.100010 |
| work_keys_str_mv | AT zhouyuling dramaticresponsetoteriprilumabandanlotinibcombinationtherapyinapatientwithegfrmutantlungadenocarcinomawhoexperiencedsmallcelltransformationmediatederlotinibresistanceafterfailureofchemotherapy AT zengliang dramaticresponsetoteriprilumabandanlotinibcombinationtherapyinapatientwithegfrmutantlungadenocarcinomawhoexperiencedsmallcelltransformationmediatederlotinibresistanceafterfailureofchemotherapy AT yangnong dramaticresponsetoteriprilumabandanlotinibcombinationtherapyinapatientwithegfrmutantlungadenocarcinomawhoexperiencedsmallcelltransformationmediatederlotinibresistanceafterfailureofchemotherapy AT zhangyongchang dramaticresponsetoteriprilumabandanlotinibcombinationtherapyinapatientwithegfrmutantlungadenocarcinomawhoexperiencedsmallcelltransformationmediatederlotinibresistanceafterfailureofchemotherapy |